TNF-α inhibitors (Adalimumab, Etanercept, Certolizumab) and IL-6 inhibitors (Tocilizumab) have been licensed by the Food and Drug Administration (FDA) for treating RA patients [53]. This evidence concerns the gene TNF and rheumatoid arthritis.